Cargando…

DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML

BACKGROUND: Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are neoplastic disorders of hematopoietic stem cells. DNA methyltransferase inhibitors, 5-azacytidine and 5-aza-2′-deoxycytidine (decitabine), benefit some MDS/AML patients. However, the role of DNA methyltransferase inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lund, Kirstin, Cole, John J, VanderKraats, Nathan D, McBryan, Tony, Pchelintsev, Nikolay A, Clark, William, Copland, Mhairi, Edwards, John R, Adams, Peter D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165364/ https://www.ncbi.nlm.nih.gov/pubmed/25315154 http://dx.doi.org/10.1186/s13059-014-0406-2

Ejemplares similares

Modeling complex patterns of differential DNA methylation that associate with gene expression changes
por: Schlosberg, Christopher E., et al.
Publicado: (2017)

Discovering high-resolution patterns of differential DNA methylation that correlate with gene expression changes
por: VanderKraats, Nathan D., et al.
Publicado: (2013)

Profiling of transcriptional and epigenetic changes during directed endothelial differentiation of human embryonic stem cells identifies FOXA2 as a marker of early mesoderm commitment
por: Howard, Lynsey, et al.
Publicado: (2013)

DNMT3B Oncogenic Activity in Human Intestinal Cancer Is Not Linked to CIMP or BRAFV600E Mutation
por: MacKenzie, Douglas J., et al.
Publicado: (2020)

Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer
por: Hiken, Jeffrey F., et al.
Publicado: (2016)

Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML
por: Chantkran, Wittawat, et al.
Publicado: (2021)

Aberrant splicing and drug resistance in AML
por: de Necochea-Campion, Rosalia, et al.
Publicado: (2016)

Critical Parameters for Efficient Sonication and Improved Chromatin Immunoprecipitation of High Molecular Weight Proteins
por: Pchelintsev, Nikolay A., et al.
Publicado: (2016)

Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML
por: Chantkran, Wittawat, et al.
Publicado: (2021)

Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients
por: Yuan, Xiao-Qing, et al.
Publicado: (2016)

DNMT3A(R882)-associated hypomethylation patterns are maintained in primary AML xenografts, but not in the DNMT3A(R882C) OCI-AML3 leukemia cell line
por: Chen, David, et al.
Publicado: (2018)

RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with DNMT3A Mutations
por: Sidorova, Olga Alexandra, et al.
Publicado: (2022)

HIRA orchestrates a dynamic chromatin landscape in senescence and is required for suppression of neoplasia
por: Rai, Taranjit Singh, et al.
Publicado: (2014)

Ectopic expression of DNA methyltransferases DNMT3A2 and DNMT3L leads to aberrant hypermethylation and postnatal lethality in mice
por: Sasaki, Keisuke, et al.
Publicado: (2019)

Mapping H4K20me3 onto the chromatin landscape of senescent cells indicates a function in control of cell senescence and tumor suppression through preservation of genetic and epigenetic stability
por: Nelson, David M., et al.
Publicado: (2016)

Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients
por: Yuan, Xiao-Qing, et al.
Publicado: (2019)

Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity
por: Copland, Mhairi
Publicado: (2022)

BRD4-mediated repression of p53 is a target for combination therapy in AML
por: Latif, Anne-Louise, et al.
Publicado: (2021)

Modulation of Dnmt3b function in vitro by interactions with Dnmt3L, Dnmt3a and Dnmt3b splice variants
por: Van Emburgh, Beth O., et al.
Publicado: (2011)

De novo DNA methyltransferases DNMT3A and DNMT3B are essential for XIST silencing for erosion of dosage compensation in pluripotent stem cells
por: Fukuda, Atsushi, et al.
Publicado: (2021)

A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone
por: Hahn, C N, et al.
Publicado: (2015)

The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML
por: Dunlap, Jennifer B., et al.
Publicado: (2019)

Graphdiyne oxide nanosheets display selective anti-leukemia efficacy against DNMT3A-mutant AML cells
por: Wang, Qiwei, et al.
Publicado: (2022)

Comparison of High-Resolution Melting (HRM) Analysis with Direct Sequencing for the Detection of DNMT3A Mutations in AML Patients
por: Moonesi, Mohammadreza, et al.
Publicado: (2022)

P456: LEUKEMOGENESIS BY AML-SPECIFIC DRIVER MUTATIONS WITHIN DNMT3A, IDH2 AND NPM1
por: Mehmetbeyoglu, Ecmel, et al.
Publicado: (2023)

Senescent mouse cells fail to overtly regulate the HIRA histone chaperone and do not form robust Senescence Associated Heterochromatin Foci
por: Kennedy, Alyssa L, et al.
Publicado: (2010)

Profiling of microRNAs in AML cells following overexpression or silencing of the VEGF gene
por: Li, Li, et al.
Publicado: (2017)

∆ DNMT3B4-del Contributes to Aberrant DNA Methylation Patterns in Lung Tumorigenesis
por: Ma, Mark Z., et al.
Publicado: (2015)

Fatty Acid Binding Protein FABP4 Mechanistically Links Obesity with Aggressive AML by Enhancing Aberrant DNA Methylation in AML Cells
por: Yan, F, et al.
Publicado: (2016)

Non-CpG methylation by DNMT3B facilitates REST binding and gene silencing in developing mouse hearts
por: Zhang, Donghong, et al.
Publicado: (2017)

The tumor suppressor MIR139 is silenced by POLR2M to promote AML oncogenesis
por: Stavast, Christiaan J., et al.
Publicado: (2021)

Effects of DNMT1 silencing on malignant phenotype and methylated gene expression in cervical cancer cells
por: Zhang, Yi, et al.
Publicado: (2011)

Clinical Features and MicroRNA Expression Patterns Between AML Patients With DNMT3A R882 and Frameshift Mutations
por: Yang, Li, et al.
Publicado: (2019)

The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively
por: Heiblig, Maël, et al.
Publicado: (2021)

CBFB-MYH11 Fusion Sequesters RUNX1 in Cytoplasm to Prevent DNMT3A Recruitment to Target Genes in AML
por: Liu, Peng, et al.
Publicado: (2021)

Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer
por: Sørensen, K D, et al.
Publicado: (2013)

Targeted disruption of DNMT1, DNMT3A and DNMT3B in human embryonic stem cells
por: Liao, Jing, et al.
Publicado: (2015)

Hedgehog signaling in cancer stem cells: a focus on hematological cancers
por: Campbell, Victoria, et al.
Publicado: (2015)

Determinants of heritable gene silencing for KRAB-dCas9 + DNMT3 and Ezh2-dCas9 + DNMT3 hit-and-run epigenome editing
por: O’Geen, Henriette, et al.
Publicado: (2022)

Methylation Abnormalities in Mammary Carcinoma: The Methylation Suicide Hypothesis
por: O’Donnell, Anne H., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_aih1e8dn3fsie02m9phr03hk11